US SB3064

Eliminates Medicare Part D deductibles for qualifying non-opioid chronic pain management drugs beginning January 1, 2026, and requires placement on the lowest cost-sharing tier

Defines qualifying drugs as FDA-approved non-opioid medications for chronic pain conditions with no therapeutically equivalent alternatives on the market and monthly costs below the specialty-tier threshold

Covers seven chronic pain conditions characterized by pain lasting more than 3 months: diabetic peripheral neuropathic pain, endometriosis, fibromyalgia, musculoskeletal pain, neuropathic pain, post-herpetic neuralgia, and trigeminal neuralgia

Prohibits Medicare Part D and MA-PD plans from requiring step therapy that mandates opioid use before accessing these non-opioid drugs, and eliminates prior authorization requirements

Applies reduced cost-sharing protections to low-income Medicare beneficiaries under the same terms